ClinicalTrials.gg
CompletedNCT06660745Updated Oct 30, 2024

The Effect of Telenursing on Self-efficacy and Treatment Adherence in Children With Cystic Fibrosis

An interventional study of telenursing-based family empowerment program in Cystic Fibrosis in Children, sponsored by Shahid Beheshti University of Medical Sciences. Completed at 1 site in Iran. Open to participants aged 9 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-10-30.

Sponsored by Shahid Beheshti University of Medical Sciences · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled May 2023, registered Oct 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
9 Years to 17 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if a telenursing-based programs works to increase self-efficacy and treatment adherence in children with Cystic fibrosis disease. It will also learn about the innovation and safety of this intervention.

Researchers will compare a group that received telenursing to a group with routine care to see if telenursing works to change the severity of cystic fibrosis (by changing behaviors).

Participants will be 25 in each group and were recruited during routine outpatient clinic visits in Mofid Children's Hospital during the period from April 2023 to October 2023. The participant information and consent form were provided during the first face-to-face meeting with the children and their caregivers. The patients were assigned to the intervention and control groups randomly, based on their medical record numbers, with even numbers placed in the intervention group and odd numbers in the control group. The selected communication platform (Skype) was installed by the researcher on the caregiver's and, if available, the child's mobile devices. The members of the intervention group were then added to a group called "Cystic Fibrosis Companions," which was created by the researcher on Skype. Patients in the control group continued with routine treatment and follow-up (monthly visits to the cystic fibrosis clinic and prescribed medications). For the intervention group, a telenursing-based program and follow-up were planned twice a week over twelve weeks. The intervention content for this study was derived from www.cff.org and www.cfsource.com websites and was developed by the research team. The content included topics related to various aspects of the disease and its management, Adjusting and moderating the physical activity program, medication regimen, Nutrition, and mental health. The intervention was conducted in two sections. The first part included a one-day educational workshop conducted through Skype for the child and their caregiver and was planned to introduce the members of the intervention group to each other and provide information on how to deliver and receive the content. In the second part of the intervention, the content was prepared based on a scheduled plan. It was in the form of a 5-10-minute audio file, video, or educational text and was uploaded on the SendBig website. Once the upload is complete, a link is provided to the user. The link was sent to the phone numbers of children with cystic fibrosis and their caregivers so that they could watch the weekly content over three months. Once it was confirmed that the link had been received (acknowledged in the "Cystic Fibrosis Companions" group) and the content had been viewed, remote follow-ups were scheduled twice a week, on Sundays and Tuesdays between 6:00 PM and 8:00 PM, using Skype messenger. During these sessions, the researcher reviewed the content sent that week and addressed any questions that the child and caregiver might have had about the content. These sessions also encourage interaction among the children, allow sharing of experiences gained from the interventions within each family, and allow feedback to be received. In order to prevent the control group from finding out about the content sent to the intervention group, a separate group with a different title was created on Skype, and all members of the control group were added to this new group. At the end of week 12, after the intervention was completed, the PRCISE and MATQ questionnaires were sent to the child's or caregiver's account and were completed in both control and intervention groups. Additionally, 4 weeks after the intervention, the same two questionnaires were completed again by both groups and finally, the results of the two groups were compared. At the end of the study, to observe ethical considerations, all contents were provided to the control group in the form of a compressed file containing videos, images, audio, and booklets. In this study, the mean age of the children was 12.24 in the intervention group, and 12.36 in the control group, 56% of the children with CF were boys, and 50% of them were in elementary school. A comparison of self-efficacy and treatment adherence scores indicated that the mean scores in the intervention and control groups were significantly different before and after the intervention, showing an increase immediately and one month after the intervention

02

Conditions studied

  • Cystic Fibrosis in Children

Keywords

  • Telenursing
  • Self-efficacy
  • Treatment adherence
  • Children
  • Cystic Fibrosis
03

In context

Treatment Adherence and Compliance

128 studies on the registry are indexed under Treatment Adherence and Compliance; 64 are open to participants now.

This study's enrollment of 50 is below the median of 86 across 107 interventional studies indexed under Treatment Adherence and Compliance.

Browse Treatment Adherence and Compliance studies →

Lead sponsor

Shahid Beheshti University of Medical Sciences is the lead sponsor of 229 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
9 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • child's fluency in speaking, writing, and reading Farsi
  • having a confirmed diagnosis of CF by a specialist
  • having been diagnosed for at least one year
  • not having any mental, or cognitive disorders or any other chronic diseases
  • not have speech, hearing, or vision problems
  • live with both parents
  • have access to a smartphone
  • be able to connect to the internet and send voice and text via Skype

Exclusion criteria

Exclusion Criteria:

  • had a Lack of interest in continuing the study
  • recent pulmonary exacerbation or hospitalization during the intervention
  • unable to follow educational sessions and provide feedback in at least two Q\&A sessions
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Intervention Group

    Intervention Group includes 25 children and their caregivers. interventional content with educational-practical and care-support model is in the form of an audio-visual file or an educational text (5-10 minutes) within a period of three months and through the content link (Send Big website) to the email address or number. It will be sent to teenager or caregiver of children with Cystic fibrosis, and after observation, remote follow-up will be done twice a week on the Skype platform, and the researcher will answer All of the questions that relate to contents. The content included topics related to various aspects of the disease and its management, Adjusting and moderating the physical activity program, medication regimen, Nutrition, and mental health.

    Other: telenursing-based family empowerment program

  • No intervention
    Control group

    in control group, No intervention will take place and the patients will receive their routine treatment plan.

Interventions

  • Othertelenursing-based family empowerment program

    The intervention was conducted in two sections. The first part included a one-day educational workshop conducted through Skype for the child and their caregiver and was planned to introduce the members of the intervention group to each other and provide information on how to deliver and receive the content. In the second part of the intervention, the content was prepared based on a scheduled plan. It was in the form of a 5-10-minute audio file, video, or educational text and was uploaded on the SendBig website. Once the upload is complete, a link is provided to the user. The link was sent to the phone numbers of children with cystic fibrosis and their caregivers so that they could watch the weekly content over three months. Once it was confirmed that the link had been received (acknowledged in the "Cystic Fibrosis Companions" group) and the content had been viewed, remote follow-ups were scheduled twice a week, on Sundays and Tuesdays between 6:00 PM and 8:00 PM, using Skype messenger.

06

What researchers measure

Primary outcomes

  1. Pediatric Rating of Chronic Illness Self-efficacy (PRCISE)

    The Pediatric Rating of Chronic Illness Self-Efficacy scale (PRCISE) was developed by Emerson et al. (2018), to investigate the level of self-efficacy in children with chronic illnesses (20), which was reevaluated and edited by the developers in the same year and finalized with 15 items. The questionnaire was scored on an 11-point Likert scale, with zero and 150 being the minimum and maximum scores, respectively. Zero is equivalent to no self-efficacy and 150 indicates the best possible self-efficacy.

    Time frame: Before the intervention, immediately after and 4 weeks after the intervention

Secondary outcomes

  1. The Modanloo Adherence to Treatment Questionnaire (MATQ)

    examine the level of adherence to treatment in patients with chronic disease (24), which consists of 40 items with 7 dimensions. The questionnaire was scored on a 6-point Likert scale, ranging from "Completely" with a score of 5 to "Not at all" with a score of 0. Some items are reverse-scored. The obtained scores fall between 0 and 200, and higher scores indicate better treatment adherence.

    Time frame: Before the intervention, immediately after and 4 weeks after the intervention

07

Study locations

1 site
  • Mofid Children Hospital
    Tehran, 1551415468, Iran
08

References and documents

Individual participant data

Plan to share: Yes — IPD used in the results publication

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: The access might be possible 6 months after the results are published.

Access criteria: The Data would be available for Researchers, students and hospital staff and it could be used for the purpose of study and research by referring to this study. the data is obtainable by Contacting with: fateme.rame@yahoo.com After sending an e-mail to the above-mentioned address in the maximum period of 1 month.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Sep 2023, 4 months.

Of 74 non-industry interventional studies with no phase under Treatment Adherence and Compliance, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's 4 months is below that.

Counting every sponsor, half of 74 studies reached it within 18 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2024
First posted
Oct 28, 2024
StartActual
May 20, 2023
Primary completionActual
Sep 21, 2023
CompletionActual
Sep 21, 2023
Last update
Oct 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06660745
Responsible party
Azam Shirinabadi Farahani (Director, Correspondent Author, member of the Pediatrics Department, Principal Investigator, Associated Professor, Shahid Beheshti University of Medical Sciences) — Principal investigator
First posted
Oct 28, 2024
Start date
May 20, 2023
Primary completion
Sep 21, 2023
Completion
Sep 21, 2023
Last update
Oct 30, 2024

Study contacts

Azam Shirinabadi Farahani, PhD
study director · PhD in Nursing, Associated Professor, Department of Pediatrics Nursing, School of Nursing & Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion